非酒精性脂肪肝患者心血管风险的研究现状
Current Status of Research on Cardiovascular Risk in Patients with Non-Alcoholic Fatty Liver Disease
摘要: 非酒精性脂肪肝(Non-Alcoholic Fatty Liver Disease, NAFLD)是慢性肝病的主要原因,被认为是代谢综合征的肝脏表现。NAFLD与胰岛素抵抗、肥胖、血脂异常、糖尿病等因素密切相关,这些因素也是心血管疾病的危险因素。研究数据表明心血管疾病是目前NAFLD患者死亡的主要原因,所以有大量的研究探讨NAFLD与心血管疾病之间的联系,其中有很多研究指出NAFLD可能是促进动脉粥样硬化和冠心病发生发展的独立危险因素。因此,进一步了解NAFLD与心血管疾病之间的关系,以及这种关系的发生机制是非常重要的,这将有利于在一定程度上减少心血管疾病的发病率和病死率。
Abstract: Non-alcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease and is considered to be the hepatic manifestation of the metabolic syndrome. NAFLD is strongly associated with insu-lin resistance, obesity, dyslipidemia and diabetes, which are also risk factors for cardiovascular disease. Research data suggest that cardiovascular disease is currently the leading cause of death in patients with NAFLD, so there are a large number of studies exploring the link between NAFLD and cardiovascular disease, with many of them pointing to the possibility that NAFLD may be an inde-pendent risk factor that promotes the development of atherosclerosis and coronary atherosclerotic heart disease. Therefore, it is important to further understand the relationship between NAFLD and cardiovascular disease, as well as the mechanisms by which this relationship occurs, which will help to reduce the incidence of cardiovascular disease and morbidity and mortality to a certain extent.
文章引用:娜迪热·巴哈提, 李雅丽. 非酒精性脂肪肝患者心血管风险的研究现状[J]. 临床医学进展, 2023, 13(11): 17451-17457. https://doi.org/10.12677/ACM.2023.13112445

参考文献

[1] Chalasani, N., Younossi, Z., Lavine, J.E., et al. (2018) The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology, 67, 328-357. [Google Scholar] [CrossRef] [PubMed]
[2] Younossi, Z.M., Golabi, P., Paik, J.M., et al. (2023) The Global Epidemi-ology of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review. Hepatology, 77, 1335-1347. [Google Scholar] [CrossRef
[3] Wang, X.J. and Malhi, H. (2018) Nonalcoholic Fatty Liver Disease. Annals of Internal Medicine, 169, Itc65-itc80. [Google Scholar] [CrossRef
[4] Quek, J., Chan, K.E., Wong, Z.Y., et al. (2023) Global Prevalence of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis in the Overweight and Obese Population: A Systematic Review and Meta-Analysis. The Lancet Gastroenterology and Hepatology, 8, 20-30. [Google Scholar] [CrossRef
[5] Younossi, Z.M., Golabi, P., De Avila, L., et al. (2019) The Global Epidemiology of NAFLD and NASH in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Journal of Hepatology, 71, 793-801. [Google Scholar] [CrossRef] [PubMed]
[6] 北京高血压防治协会, 北京糖尿病防治协会, 北京慢性病防治与健康教育研究会, 等. 基层心血管病综合管理实践指南2020[J]. 中国医学前沿杂志(电子版), 2020, 12(8): 前插1, 1-73.
[7] Sinn, D.H., Kang, D., Chang, Y., et al. (2020) Non-Alcoholic Fatty Liver Disease and the Incidence of Myocardial Infarction: A Cohort Study. Journal of Gastroenterology and Hepatology, 35, 833-839. [Google Scholar] [CrossRef] [PubMed]
[8] Mahmood, S.S., Levy, D., Vasan, R.S., et al. (2014) The Framingham Heart Study and the Epidemiology of Cardiovascular Disease: A Historical Perspective. The Lancet, 383, 999-1008. [Google Scholar] [CrossRef
[9] Tomah, S., Alkhouri, N. and Hamdy, O. (2020) Nonalco-holic Fatty Liver Disease and Type 2 Diabetes: Where Do Diabetologists Stand? Clinical Diabetes and Endocrinology, 6, Article No. 9. [Google Scholar] [CrossRef] [PubMed]
[10] Zhang, M., Deng, Q., Wang, L., et al. (2018) Prevalence of Dyslipidemia and Achievement of Low-Density Lipoprotein Cholesterol Targets in Chinese Adults: A Nationally Repre-sentative Survey of 163,641 Adults. International Journal of Cardiology, 260, 196-203. [Google Scholar] [CrossRef] [PubMed]
[11] Hsiao, C.-C., Teng, P.-H., Wu, Y.-J., et al. (2021) Severe, but Not Mild to Moderate, Non-Alcoholic Fatty Liver Disease Associated with Increased Risk of Subclinical Coronary Ath-erosclerosis. BMC Cardiovascular Disorders, 21, Article No. 244. [Google Scholar] [CrossRef] [PubMed]
[12] Mcnally, B.B., Rangan, P., Wijarnpreecha, K., et al. (2023) Fi-brosis-4 Index Score Predicts Concomitant Coronary Artery Diseases across the Spectrum of Fatty Liver Disease. Diges-tive Diseases and Sciences, 68, 3765-3773. [Google Scholar] [CrossRef] [PubMed]
[13] Mantovani, A., Csermely, A., Petracca, G., et al. (2021) Non-Alcoholic Fatty Liver Disease and Risk of Fatal and Non-Fatal Cardiovascular Events: An Updated Systematic Re-view and Meta-Analysis. The Lancet Gastroenterology and Hepatology, 6, 903-913. [Google Scholar] [CrossRef
[14] Yu, M.M., Tang, X.L., Zhao, X., et al. (2022) Plaque Pro-gression at Coronary CT Angiography Links Non-Alcoholic Fatty Liver Disease and Cardiovascular Events: A Prospec-tive Single-Center Study. European Radiology, 32, 8111-8121. [Google Scholar] [CrossRef] [PubMed]
[15] Loomba, R., Friedman, S.L. and Shulman, G.I. (2021) Mecha-nisms and Disease Consequences of Nonalcoholic Fatty Liver Disease. Cell, 184, 2537-2564. [Google Scholar] [CrossRef] [PubMed]
[16] Anstee, Q.M., Mantovani, A., Tilg, H., et al. (2018) Risk of Car-diomyopathy and Cardiac Arrhythmias in Patients with Nonalcoholic Fatty Liver Disease. Nature Reviews Gastroenter-ology & Hepatology, 15, 425-439. [Google Scholar] [CrossRef] [PubMed]
[17] Duan, Y., Pan, X., Luo, J., et al. (2022) Association of Inflam-matory Cytokines with Non-Alcoholic Fatty Liver Disease. Frontiers in Immunology, 13, Article ID: 880298. [Google Scholar] [CrossRef] [PubMed]
[18] Xiong, J., Chen, X., Zhao, Z., et al. (2022) A Potential Link be-tween Plasma Short-Chain Fatty Acids, TNF-α Level and Disease Progression in Non-Alcoholic Fatty Liver Disease: A Retrospective Study. Experimental and Therapeutic Medicine, 24, Article No. 598. [Google Scholar] [CrossRef] [PubMed]
[19] Fricker, Z.P., Pedley, A., Massaro, J.M., et al. (2019) Liver Fat Is Associated with Markers of Inflammation and Oxidative Stress in Analysis of Data from the Framingham Heart Study. Clinical Gastroenterology and Hepatology, 17, 1157-1164.e4. [Google Scholar] [CrossRef] [PubMed]
[20] Kaptoge, S., Di Angelantonio, E., Pennells, L., et al. (2012) C-Reactive Protein, Fibrinogen, and Cardiovascular Disease Prediction. The New England Journal of Medicine, 367, 1310-1320. [Google Scholar] [CrossRef
[21] Tang, W.H.W., Bäckhed, F., Landmesser, U., et al. (2019) Intestinal Microbiota in Cardiovascular Health and Disease: JACC State-of-the-Art Review. Journal of the Amer-ican College of Cardiology, 73, 2089-2105. [Google Scholar] [CrossRef] [PubMed]
[22] Duewell, P., Kono, H., Rayner, K.J., et al. (2010) NLRP3 Inflam-masomes Are Required for Atherogenesis and Activated by Cholesterol Crystals. Nature, 464, 1357-1361. [Google Scholar] [CrossRef] [PubMed]
[23] Bäck, M., Yurdagul, A., Tabas, I., et al. (2019) Inflammation and Its Resolution in Atherosclerosis: Mediators and Therapeutic Opportunities. Nature Reviews Cardiology, 16, 389-406. [Google Scholar] [CrossRef] [PubMed]
[24] Petta, S., Argano, C., Colomba, D., et al. (2015) Epicardial Fat, Cardiac Geometry and Cardiac Function in Patients with Non-Alcoholic Fatty Liver Disease: Association with the Sever-ity of Liver Disease. Journal of Hepatology, 62, 928-933. [Google Scholar] [CrossRef] [PubMed]
[25] Liu, B., Li, Y., Li, Y., et al. (2019) Association of Epicardial Adipose Tissue with Non-Alcoholic Fatty Liver Disease: A Me-ta-Analysis. Hepatology International, 13, 757-765. [Google Scholar] [CrossRef] [PubMed]
[26] Packer, M. (2018) Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium. Journal of the American College of Cardiology, 71, 2360-2372. [Google Scholar] [CrossRef] [PubMed]
[27] Madonna, R., Massaro, M., Scoditti, E., et al. (2019) The Epicardial Adipose Tissue and the Coronary Arteries: Dangerous Liaisons. Cardiovascular Research, 115, 1013-1025. [Google Scholar] [CrossRef] [PubMed]
[28] Grunwald, S.A., Haafke, S., Grieben, U., et al. (2022) Statins Aggravate the Risk of Insulin Resistance in Human Muscle. International Journal of Molecular Sciences, 23, Article No. 2398. [Google Scholar] [CrossRef] [PubMed]
[29] Flannery, C., Dufour, S., Rabøl, R., et al. (2012) Skeletal Muscle Insu-lin Resistance Promotes Increased Hepatic de Novo Lipogenesis, Hyperlipidemia, and Hepatic Steatosis in the Elderly. Diabetes, 61, 2711-2717. [Google Scholar] [CrossRef] [PubMed]
[30] Ke, Z., Huang, R., Xu, X., et al. (2023) Long-Term High Level of Insulin Resistance Is Associated with an Increased Prevalence of Coronary Artery Calcification: The CARDIA Study. Journal of the American Heart Association, 12, e028985. [Google Scholar] [CrossRef
[31] Martín-Saladich, Q., Simó, R., Aguadé-Bruix, S., et al. (2023) Insights into Insulin Resistance and Calcification in the Myocardium in Type 2 Diabetes: A Coronary Artery Analysis. International Journal of Molecular Sciences, 24, Article No. 3250. [Google Scholar] [CrossRef] [PubMed]
[32] Di Pino, A. and Defronzo, R.A. (2019) Insulin Resistance and Athero-sclerosis: Implications for Insulin-Sensitizing Agents. Endocrine Reviews, 40, 1447-1467. [Google Scholar] [CrossRef] [PubMed]
[33] Cimmino, G., Muscoli, S., De Rosa, S., et al. (2023) Evolving Con-cepts in the Pathophysiology of Atherosclerosis: From Endothelial Dysfunction to Thrombus Formation through Multiple Shades of Inflammation. Journal of Cardiovascular Medicine (Hagerstown), 24, e156-e167. [Google Scholar] [CrossRef
[34] Francque, S.M., Van Der Graaff, D. and Kwanten, W.J. (2016) Non-Alcoholic Fatty Liver Disease and Cardiovascular Risk: Pathophysiological Mechanisms and Implications. Journal of Hepatology, 65, 425-443. [Google Scholar] [CrossRef] [PubMed]
[35] Stahl, E.P., Dhindsa, D.S., Lee, S.K., et al. (2019) Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 73, 948-963. [Google Scholar] [CrossRef] [PubMed]
[36] Vita, T., Murphy, D.J., Osborne, M.T., et al. (2019) As-sociation between Nonalcoholic Fatty Liver Disease at CT and Coronary Microvascular Dysfunction at Myocardial Per-fusion PET/CT. Radiology, 291, 330-337. [Google Scholar] [CrossRef] [PubMed]
[37] Xiang, W., Yang, Y., Weng, L., et al. (2023) Hyperhomocyste-inemia Activates NLRP3 Inflammasome to Cause Hepatic Steatosis and Insulin Resistance via MDM2-Mediated Ubiqui-tination of HSF1. International Immunopharmacology, 118, Article ID: 110085. [Google Scholar] [CrossRef] [PubMed]
[38] Fu, L., Wang, Y. and Hu, Y.Q. (2023) Association between Homocysteine and Nonalcoholic Fatty Liver Disease: Mendelian Randomisation Study. European Journal of Clinical Investigation, 53, e13895. [Google Scholar] [CrossRef] [PubMed]
[39] Gao, Y., Guo, Y., Hao, W., et al. (2023) Correlation Analysis and Diagnos-tic Value of Serum Homocysteine, Cystatin C and Uric Acid Levels with the Severity of Coronary Artery Stenosis in Pa-tients with Coronary Heart Disease. International Journal of General Medicine, 16, 2719-2731. [Google Scholar] [CrossRef
[40] Sharpton, S.R., Ajmera, V. and Loomba, R. (2019) Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function. Clinical Gastroenterology and Hepatology 17, 296-306. [Google Scholar] [CrossRef] [PubMed]
[41] Loomba, R., Seguritan, V., Li, W., et al. (2017) Gut Microbi-ome-Based Metagenomic Signature for Non-Invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metabolism, 25, 1054-1062.e5. [Google Scholar] [CrossRef] [PubMed]
[42] Jie, Z., Xia, H., Zhong, S.L., et al. (2017) The Gut Microbiome in Atherosclerotic Cardiovascular Disease. Nature Communications, 8, Article No. 845. [Google Scholar] [CrossRef] [PubMed]
[43] Shen, F., Zheng, R.D., Sun, X.Q., et al. (2017) Gut Microbiota Dysbiosis in Patients with Non-Alcoholic Fatty Liver Disease. Hepatobiliary & Pancreatic Diseases International, 16, 375-381. [Google Scholar] [CrossRef
[44] Aron-Wisnewsky, J., Vigliotti, C., Witjes, J., et al. (2020) Gut Microbiota and Human NAFLD: Disentangling Microbial Signatures from Metabolic Disorders. Nature Reviews Gastroenterology & Hepatology, 17, 279-297. [Google Scholar] [CrossRef] [PubMed]
[45] Nian, F., Zhu, C., Jin, N., et al. (2023) Gut Microbiota Metabolite TMAO Promoted Lipid Deposition and Fibrosis Process via KRT17 in Fatty Liver Cells in Vitro. Biochemical and Bio-physical Research Communications, 669, 134-142. [Google Scholar] [CrossRef] [PubMed]